Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Evelo Fiscal Q4 2019 Earnings Report - CapyFin

Evelo

EVLO · NASDAQ🇺🇸

View Company

Overview Earnings

Dividends Seasonality Metrics

Q4 2023 0.00%Q3 2023 -7.64%Q2 2023 +32.31%Q1 2023 +2.90%Q4 2022 -17.78%Q3 2022 +3.30%Q2 2022 -7.12%Q1 2022 -20.29%Q4 2021 +29.36%Q3 2021 +10.21%Q2 2021 -0.86%Q1 2021 +8.77%Q4 2020 +14.50%Q3 2020 -12.94%Q2 2020 -1.55%Q1 2020 -5.71%Q4 2019 +1.83%Q3 2019 -3.28%Q2 2019 +3.95%Q1 2019 +0.83%Q4 2018 +1.25%Q3 2018 +0.21%Q2 2018 -3.35%Q1 2018 +1.78%Q4 2017 Q3 2017 Q2 2017 Q1 2017

Feb 13, 2020

•

Dec 31, 2019

Evelo Q4 2019 Earnings Report

Reported financial results and business highlights for Q4 and full year 2019.

Key Takeaways

Evelo Biosciences reported positive clinical data supporting the validation of its novel platform and demonstrating the targeting of SINTAX™ to drive clinical effects in individuals with psoriasis. Multiple clinical readouts are planned across the inflammation and oncology portfolio in 2020, and the development of EDP1815 is progressing.

Strong 2019 marked by clinical data that validates platform

Lead inflammation candidate EDP1815 showed positive clinical data across two separate cohorts

EDP1815 Phase 2 study initiation expected in Q2 2020

Multiple clinical readouts across inflammation and oncology portfolio expected throughout 2020